Vaccination of Fusion-VAC-XS15

Phase 1Small molecule

UUniversity Hospital Tuebingen

Vaccination of Fusion-VAC-XS15 is one of 53 small molecule programs targeting Liver Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver CancerRecruiting

Liver CancerPhase 1

Recruiting

Competition

Competitive Landscape

61 competitors in Liver Cancer

#DrugCompanyPhaseTrials

Taxol

Idamycin

Blenoxane

Opdivo

13 5

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

1 6

Eloxatin

Teva

Phase 3

8 7

Lenvima

Eisai

Phase 3

7 8

Alimta

Bicnu

Rapamune

PPrism Pharmaceuticals

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Liver Cancer

NCT06789198

Clinical

Trials by Indication[1]

Liver Cancer1 trial

FusionVAC22_02: DNAJB1-PRKACA Fusion Transcript-based Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Oncogenic Driver Fusion

Recruiting·UUniversity Hospital Tuebingen·Phase 1·NCT06789198·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Vaccination of Fusion-VAC-XS15. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vaccination of Fusion-VAC-XS15 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vaccination of Fusion-VAC-XS15. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital Tuebingen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity Hospital Tuebingen

Vaccination of Fusion-VAC-XS15

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Liver Cancer1 trial

References

Drug Info

Quick Facts

Related News